Humana’s Medicare Ratings Recovery Signals a Major Earnings Turnaround

Medicare Quality Ratings Deliver a Major Boost to Humana

Humana (HUM) shares jumped approximately 12% to 16% during Friday's trading session on October 9, 2026, after the health insurer reported a substantial improvement in its Medicare Advantage Star Ratings. The company announced that 95% of its members will be enrolled in plans rated four stars or higher for 2027, compared with approximately 20% under the previous ratings cycle.

The results exceeded J.P. Morgan analysts' expectations of 60% to 70% and marked a significant reversal from the ratings deterioration that had weighed on Humana's profitability. Because higher-rated plans qualify for federal quality bonus payments, the improvement has important implications for the company's earnings recovery beginning in 2028.

Key Points

• Humana's Medicare Advantage ratings improved sharply, with 95% of members in four-star-or-higher plans for 2027, significantly exceeding Wall Street expectations.
• Higher ratings restore eligibility for federal quality bonuses, strengthening Humana's potential revenue and margin recovery in 2028 rather than immediately in 2027.
• Humana outperformed major insurance competitors, while UnitedHealth and CVS experienced declines in their shares of members enrolled in highly rated plans.

Humana Reverses Its Medicare Advantage Ratings Decline

Humana's latest Medicare Advantage Star Ratings represent a substantial improvement after two years of pressure on the company's quality scores.

The Centers for Medicare and Medicaid Services (CMS) evaluates Medicare Advantage and prescription drug plans annually using a five-star system. Ratings reflect measures such as clinical outcomes, preventive care, customer service and member experience.

Plans receiving at least four stars qualify for federal quality bonus payments, making the ratings an important financial consideration for participating insurers.

Humana previously had more than 90% of its Medicare Advantage membership in highly rated plans. That percentage fell sharply during the 2025 and 2026 ratings cycles, reducing the company's eligibility for quality-related payments.

The latest results reverse much of that deterioration.

For 2027, Humana reported that 95% of its Medicare Advantage members are enrolled in plans rated at least four stars. Approximately 42% are in plans rated 4.5 stars.

The company now has 18 Medicare Advantage contracts rated four stars or higher, including six rated 4.5 stars. That represents 11 additional qualifying contracts compared with the previous year.

Importantly, Humana's largest Medicare Advantage contract, H5216, regained its four-star rating.

The contract had been a central concern for analysts because of its size and importance to the company's quality bonus eligibility.

Humana also reported that its prescription drug plan contract received a 4.5-star rating.

The improvement follows an extended operational effort to strengthen clinical performance and member engagement.

According to the company, outreach initiatives helped tens of thousands of members complete overdue cancer screenings and diabetes-related eye examinations.

Those efforts contributed to earlier identification of previously undetected medical conditions while improving the quality measures used in CMS evaluations.

CEO Jim Rechtin credited Humana employees for the improvement, emphasizing the company's focus on coordinated care and member health outcomes.

Why Did Humana Stock Surge on the Ratings Announcement?

The market's reaction reflected both the magnitude of Humana's ratings improvement and its potential financial implications.

Before the announcement, J.P. Morgan analysts expected approximately 60% to 70% of Humana's Medicare Advantage membership to qualify for four-star-or-higher plans.

The reported 95% result substantially exceeded that range.

The improvement matters because Medicare Advantage quality bonuses can represent a significant source of revenue for insurers.

Across the industry, federal quality bonus payments are expected to exceed $13 billion this year.

For Humana, the return of its largest contracts to the qualifying threshold strengthens the company's ability to recover payments that had been affected by earlier ratings declines.

However, the timing is important.

The 2027 Star Ratings determine quality bonus payments for 2028, not 2027.

That means the financial benefits associated with the latest ratings will not immediately appear in Humana's current earnings.

Analysts have nevertheless begun assessing the potential impact.

TD Cowen analyst Ryan Langston estimated that the ratings recovery could generate at least $3 billion in additional revenue during 2028.

Oppenheimer estimated approximately $3.6 billion in revenue associated with the improvement, with a potential earnings contribution of $20 per share if that revenue were retained as projected.

Those figures are analyst estimates rather than confirmed company earnings guidance.

The distinction matters because additional Medicare revenue does not translate directly into profit.

Medical expenses, benefit costs, provider agreements and operating efficiency will determine how much of the additional revenue ultimately contributes to earnings.

Humana's consolidated operating profitability has also been under pressure.

Its earnings before interest and taxes margin declined from 4.3% in 2023 to approximately 2.3% over the latest twelve-month period.

Management is targeting an individual Medicare Advantage pretax margin of at least 3% by 2028.

That target is separate from the company's consolidated operating margin, but improved quality bonus eligibility supports the broader recovery effort.

In a securities filing, Humana said it remains positioned to unlock the business's earnings potential by 2028.

How Does Humana's Recovery Compare With Other Insurers?

Humana's ratings improvement stands out because much of the broader Medicare Advantage industry experienced weaker results for 2027.

According to federal data, approximately 37% of Medicare Advantage plans with prescription drug coverage earned four stars or higher, down from 44% in 2026.

The average star rating also declined slightly.

CMS introduced changes to its evaluation methodology, including adjustments to performance measures and thresholds, making it more difficult for some insurers to maintain higher ratings.

Against that backdrop, Humana's improvement was particularly significant.

J.P. Morgan estimates that UnitedHealth Group (UNH) will have approximately 67% of its Medicare Advantage members in four-star-or-higher plans for 2027, compared with 81% previously.

CVS Health (CVS), through its Aetna insurance business, is expected to see that percentage decline to approximately 70% from 84%.

Both companies remain major Medicare Advantage participants, but their latest ratings trends contrast with Humana's recovery.

Their stock market reactions were also more restrained.

CVS shares declined during Friday's session, while UnitedHealth traded modestly higher.

Alignment Healthcare (ALHC) experienced a much sharper negative reaction after its largest contract received a 3.5-star rating for 2027.

The company said it disagreed with the assessment and was considering administrative and legal remedies.

Alignment shares fell sharply following the announcement, reflecting concerns about the potential loss of future bonus payments.

These different outcomes demonstrate how Medicare Advantage ratings can materially influence financial expectations across the managed-care industry.

For Humana, the improvement also arrives shortly before the annual Medicare enrollment period, which runs from October 15 through December 7.

Higher ratings may strengthen the company's competitive position as eligible beneficiaries compare coverage options.

However, Humana is also reducing its geographic footprint.

The company said its 2027 Medicare Advantage coverage will extend to just over 80% of U.S. counties, compared with approximately 85% in the current year.

That reduction is part of a broader industry effort to withdraw from less profitable markets and improve operating performance.

Consequently, Humana's longer-term recovery will depend on both the financial benefits of higher ratings and its ability to manage medical costs, membership changes and profitability.

What It Means for Investors

Humana's latest Star Ratings represent an important development in the company's multiyear earnings recovery.

The announcement addresses one of the major concerns that had weighed on the insurer: the loss of federal quality bonus eligibility following earlier ratings declines.

By restoring most of its Medicare Advantage membership to qualifying plans, Humana has strengthened the financial outlook for 2028.

The results also provide evidence of operational improvement, particularly in preventive care and member engagement.

However, the market has already responded with a substantial increase in Humana's share price.

That reaction reflects expectations that the ratings recovery will eventually translate into higher revenue and improved margins.

The key distinction for investors is between restored eligibility for bonus payments and realized earnings growth.

Humana must still manage medical spending, benefit costs and operating expenses to convert additional payments into sustainable profitability.

The company also faces the effects of reduced plan availability and changes in Medicare Advantage enrollment.

Another consideration is that CMS Star Ratings are recalculated annually, meaning the company must continue meeting quality standards to preserve its improved position.

The next important developments will be Humana's enrollment trends, medical cost performance, future earnings guidance and progress toward its 2028 Medicare Advantage margin target.

Conclusion

Humana's Medicare Advantage ratings recovery marks a significant improvement in the company's financial outlook.

With 95% of members now associated with four-star-or-higher plans for 2027, the insurer has exceeded analyst expectations and regained eligibility for important federal quality bonuses.

The improvement also distinguishes Humana from several major competitors whose ratings performance weakened.

Friday's sharp stock advance reflects the market's reassessment of Humana's potential earnings recovery.

Nevertheless, the financial impact will largely emerge in 2028, and higher bonus eligibility alone does not guarantee stronger profits.

Humana's ability to control medical costs, manage enrollment and achieve its targeted margins will determine how much of the ratings improvement translates into lasting financial performance.

FAQs

Why did Humana stock rise sharply on October 9, 2026?

Humana shares surged after the company announced that 95% of its Medicare Advantage members would be enrolled in plans rated four stars or higher for 2027, significantly exceeding analyst expectations and improving its eligibility for future federal quality bonus payments.

What are Medicare Advantage Star Ratings?

Medicare Advantage Star Ratings are annual quality assessments issued by the Centers for Medicare and Medicaid Services. Plans receive ratings from one to five stars based on measures including clinical care, preventive services, customer experience and member satisfaction.

When will Humana benefit financially from its improved ratings?

The 2027 Medicare Advantage Star Ratings determine quality bonus payments for 2028. Humana's improved ratings therefore strengthen its 2028 revenue outlook, although the ultimate earnings impact will depend on medical costs and operating performance.

How did Humana perform compared with UnitedHealth and CVS?

Humana reported that 95% of its Medicare Advantage members will be in four-star-or-higher plans for 2027. J.P. Morgan estimates approximately 67% for UnitedHealth and 70% for CVS Health, both representing declines from their previous ratings.

What risks remain for Humana after the ratings improvement?

Humana continues to face medical cost pressures, reduced Medicare Advantage coverage in some markets and the challenge of translating higher bonus payments into stronger profitability. CMS also recalculates Star Ratings annually, making sustained quality performance important.

This article was created with AI assistance and reviewed by an editor. For details, please refer to our Terms of Use.

Go Beyond the Market Brief with Market Edge

Follow SharperTrades’ complete approach to trading and investing, combining active trade opportunities through Block Orders, long-term research through Stock Investor, and structured market education through the Swing Trading Masterclass. Try Market Edge for $19 your first month →

Explore Research with Stock Investor

Stock Investor is SharperTrades’ platform for long-term investing research and portfolio management. Members receive research reports, portfolio updates, conviction tracking, and in-depth analysis designed to support disciplined investment decisions.

Explore Active Trading & Income Strategies

Block Orders tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities.

For options-focused traders, Essential Option Income provides a structured approach to options income strategies, while Pro Option Trader offers a broader range of options strategies and trade opportunities.

Think More Clearly with SteadyCapital

SteadyCapital is SharperTrades’ decision-support system for long-term investors, built around the SteadyCapital Method™. Review investment ideas, challenge assumptions, evaluate valuation and risk, compare companies, and think through important buy, hold, add, trim, or sell decisions before you act.

Risk Disclosure

All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full Risk Disclosure for additional information.